Autoimmune Diseases

Ruxolitinib cream is showing promise as a potential treatment for lichen planus, a chronic autoimmune skin disease with no FDA-approved options. Characterized by itchy, purple lesions, lichen planus can significantly impact patients' quality of life. A recent phase 2 trial highlights the efficacy and safety of ruxolitinib cream in clearing lesions and providing symptom relief. As research continues, ruxolitinib could become a transformative therapy in managing lichen planus for those suffering from this debilitating condition.

Explore some of the key insights from EADV 2023: Prof. Thierry Passeron illuminates pigmentary disorders breakthroughs, Dr Raj Chovatiya unveils atopic dermatitis innovations, Prof. Leonardo Marini sheds light on aesthetic medicine developments, and Prof. Dedee Murrell reveals treatment progress exciting clinical trials and key discoveries in blistering and autoimmune diseases. Filmed in coverage of the EADV Annual Meeting. This content was developed by Touch Medical Media and is not affiliated with the  European Academy of Dermatology & Venereology  (EADV) or the congress. 

There are a number of cutaneous manifestations associated with lupus erythematosus, pushing forward for innovative approaches and emerging investigational therapeutics in clinical trials. touchDERMATOLOGY were delighted to speak with Dr. Victoria P. Werth (University Perelman School of Medicine, Philadelphia, PA, USA) to discuss the key developments, novel insights and future directions in the field of lupus erythematosus. This information is provided solely by Touch Medical Media and is independent of any sponsorship or affiliation with the European Academy of Dermatology & Venereology (EADV). The presentation 'New insights and therapeutic approaches in Lupus Erythematosus' (Presentation ID PLB-03) was presented at EADV 2023, Berlin, 11-14 October 2023 #EADVCongress. Questions Could you tell us a little about lupus erythematosus and the unmet needs in its treatment? (0:18) What cutaneous manifestations are associated with lupus erythematosus? (1:45) What novel therapeutic approaches are changing the way that lupus is treated? (2:16) What investigational therapeutics show promise for lupus erythematosus in clinical trials? (3:10) What are the key developments and future directions in the field of lupus erythematosus? (5:00) Disclosures: Victoria Werth has received grants from Celgene, Amgen, Janssen, Biogen, Gilead, Viela; Horizon therapeutics, and Ventus; and is/has been a consultant (and received honorarium) for Astra-Zeneca, Pfizer, Biogen, Celgene, Resolve, Janssen, Gilead, Lilly, BMS, Nektar, Abbvie, Viela, GSK, EMD Serona, Sanofi, Anaptysbio, Amgen, Merck Kyowa Kirin, Rome Therapeutics, and Xencor; and is on the Lupus Foundation of America advisory board. Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones and Katey Gabrysch. Filmed in coverage of the EADV Annual Meeting. This content was developed by Touch Medical Media and is not affiliated with the  European Academy of Dermatology & Venereology  (EADV) or the congress. 

Current treatment options for autoimmune blistering diseases (AIBDs) remain limited, with effective treatments associated with adverse events or issues with long-term use. Insights into the pathogenesis of AIBDs are providing promise for potential therapeutic targets. In this interview touchDERMATOLOGY spoke with Expert Faculty member Prof. Dedee F. Murrell (UNSW Medical School, Sydney, Australia) around the challenges in the current treatment landscape for AIBDs, advances in therapeutics in recent years, and the importance of understanding the pathogenesis of AIBDs in guiding future therapeutic targets. Questions Could you describe the current treatment landscape for autoimmune blistering diseases (AIBDs) and the unmet needs that exist? (0:37) What issues are associated with high level immunosuppression when treating AIBDs? (2:31) What have been the most important recent advances in treatments for AIBDs? (3:39) How will advances in the understanding of AIBD pathogenesis guide future therapeutic targets? (6:04) How important will translational medicine be for improving outcomes in patients with AIBDs? (8:19) Disclosures: Dedee Murrell discloses serving on advisory boards for Argenx, Sanofi, Principia, Janssen, Lilly, Almirall, Roche, Cocreator PDAI, BPDAI, MMPDAI, Abbvie, Novartis, Kineska, Amryt, Castle Creek, Rheacell, and Shire. Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones and Katey Gabrysch. Filmed in coverage of the EADV Annual Meeting. This content was developed by Touch Medical Media and is not affiliated with the  European Academy of Dermatology & Venereology  (EADV) or the congress. 

DeterMine (NCT03813160) was a phase 3 randomized, double-blind, placebo-controlled study investigating the efficacy and safety of lenabasum for the treatment of dermatomyositis. It was a pleasure to talk with Prof. Victoria P. Werth (University of Pennsylvania, Philadelphia, PA, USA) to discuss the aims, design, eligibility criteria and findings of the phase 3 study. This information […]

The treatment paradigm for pemphigus remains with many unmet needs, the current standard of care remains to be systemic corticosteroids, which cause many phycological and metabolic side effects, in the past few years rituximab has been approved alongside steroids; however takes months to work. touchIMMUNOLOGY were delighted to talk with Prof. Dedee F. Murrell (St […]